Cue Biopharma, Inc. (NASDAQ:CUE) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET
Company Participants
Dan Passeri - CEO
Matteo Levisetti - Chief Medical Officer
Ken Pienta - Clinical Advisory
Anish Suri - President and Chief Scientific Officer
Kerri Millar - CFO
Sara Pai - Surgical Oncologist and Director, Translational Head and Neck Cancer Research, Mass General Hospital
Conference Call Participants
Ted Tenthoff - Piper Sandler
Ren Benjamin - JMP Securities
Mark Breidenbach - Oppenheimer
Stephen Willey - Stifel
Operator
Greetings, and welcome to the Cue Biopharma Fourth Quarter and Full Year 2022 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.
I would now like to turn the conference over to your host, Mr. Dan Passeri, Chief Executive Officer. Please go ahead.
Dan Passeri
Yes. Thank you, and good afternoon, everyone. As a reminder, this conference will be recorded and available on our website for the next 30 days. Also as a reminder, those listening in, just be aware of the webcast, you need to advance the slides as you are listening, and we'll notify you which slide we're on at a given time.
Joining me on today's call is Dr. Matteo Levisetti, our Chief Medical Officer; Dr. Ken Pienta, now in the role as a Clinical Advisory Cue; Dr. Anish Suri, our President and Chief Scientific Officer; and Kerri Millar, Chief Financial Officer.
Also joining us briefly on today's call is Dr. Sara Pai, Surgical Oncologist and Director of Translational Head and Neck Cancer Research at the Mass General Hospital. She is an investigator in our ongoing trial with CUE-101. We'll provide a brief perspective of clinical observations to date. In addition to Dr. Pienta, Dr. Pai has also recently become a clinical adviser to Cue Biopharma helping to define our clinical strategies going forward.
As shown here on Slide 2, this presentation and overview may contain some forward-looking statements, and any forward-looking statements made during this call represents the company's views as of today, March 21, 2023.
On the next slide, please. You'll see our agenda for today's call. Just want to please note that on this slide under the financial results, that's meant to read fourth quarter 2022, not third quarter. Apologies for that. We just noticed that before the call.
Okay. I'll begin by providing an overview and status update of our current corporate positioning, and we'll describe our competitive advantage, which we believe places us in a differentiated strategic position of strength and opportunity despite the present challenges of the capital markets. We're also well positioned with capital into the second half of '24. And importantly, our platform has generated numerous programs at various stages of development, representing multiple partnering opportunities.